Premium
Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.
Author(s) -
Seideman P,
Borg KO,
Haglund K,
Bahr C
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03044.x
Subject(s) - alprenolol , blood pressure , tachycardia , medicine , angina , anesthesia , heart rate , pharmacology , propranolol , myocardial infarction
The antihypertensive effect of alprenolol has been studied before, during and after additional pentobarbitone treatment. The combined alprenolol‐pentobarbitone treatment significantly decreased alprenolol levels by 59% and 4‐hydroxyalprenolol by 24%. The effect was significant after three doses and declined over 4‐5 days after pentobarbitone withdrawal. The decreased alprenolol plasma levels were associated with increased pulse rate (6%), and systolic (8%) and diastolic (9%) blood pressure. The inhibition of exercise tachycardia by alprenolol was reduced by 18% at the end of pentobarbitone treatment compared to initial monotherapy with alprenolol. The interaction is probably clinically important in those patients with hypertension and angina pectoris that are treated with barbiturates and alprenolol.